Pfizer Japan Staffers To Buy Out Research Lab From U.S. Parent (Japan)
This article was originally published in PharmAsia News
Executive Summary
Approximately 80 researchers at Pfizer's Aichi Prefecture laboratory plan to take over the operations and assets through an employee buyout. Pfizer is closing the laboratory, a decision that prompted the researchers to decide to establish a new-drug venture and buy facilities and the rights to develop substances for potential new drugs from Pfizer. The researchers will take a controlling stake in this venture in April 2008, with 10 billion yen to be raised from investment funds in Japan and abroad. The laboratory's director, Atsushi Nagahisa, is expected to be named president of the venture, which will likely go public in several years. Pfizer intends to accept the employee buyout, and may take a stake in the venture. (Click here for more - May Require Paid Subscription
You may also be interested in...
Pfizer Avoids Japan R&D Layoffs With Creation Of New Business
Pfizer is spinning off some of its Nagoya, Japan, research site into a venture-backed start-up called RaQualia Pharma Inc., the company reported July 3
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.